Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study

OBJECTIVE: To evaluate the efficacy and safety of pegylated interferon alpha-2b (PEG IFN-α2b) administered in conjunction with the standard of care (SOC) in subjects with moderate coronavirus disease-19 (COVID-19). METHODS: In this study, adult subjects with confirmed moderate COVID-19 were randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhushan B L, Shashi, Wanve, Sunil, Koradia, Parshottam, Bhomia, Vinay, Soni, Pravin, Chakraborty, Sisir, Khobragade, Akash, Joshi, Shashank, Mendiratta, Sanjeev Kumar, Kansagra, Kevin Kumar, Parihar, Anurag, Sharma, Sunil, Patel, Jatin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379820/
https://www.ncbi.nlm.nih.gov/pubmed/34428542
http://dx.doi.org/10.1016/j.ijid.2021.08.044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379820/
https://www.ncbi.nlm.nih.gov/pubmed/34428542
http://dx.doi.org/10.1016/j.ijid.2021.08.044

Ejemplares similares